cp wire

CP Wire Articles

NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH

NGM Bio today announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological measures of disease in nonalcoholic... read more

Sat, 04/14/18 - 10:09 am
Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver... read more

Fri, 04/13/18 - 12:52 pm
MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today presented the positive... read more

Fri, 04/13/18 - 12:42 pm
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic... read more

Fri, 04/13/18 - 12:10 pm
Allergan Announces Launch of the TrueTear Intranasal Neurostimulation Device


Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase... read more

Fri, 04/13/18 - 09:47 am

Pages